Active substanceCeftriaxoneCeftriaxone
Similar drugsTo uncover
  • Azaran
    powdersolution w / m in / in 
    Hemofarm AD     Serbia
  • Axon
    powder w / m in / in 
  • Betasporin
    powdersolution w / m in / in 
    Laboratorios Atral SA     Portugal
  • Biotrakson
    powdersolution w / m in / in 
  • Broadssef-S
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • IFICEF®
    powder w / m in / in 
  • Lendacin®
    powder d / infusion 
    Lek dd     Slovenia
  • Lifaxon
    powdersolution w / m in / in 
    FARMGID CJSC     Russia
  • Medaxon
    powder w / m in / in 
    Medocemi Co., Ltd.     Cyprus
  • Movigip®
    powder w / m in / in 
  • Oframax®
    powdersolution w / m in / in 
  • Rocefin®
    powder w / m 
    Hoffmann-La Roche Ltd.     Switzerland
  • Rocefin®
    powder in / in 
  • Rocefin®
    powder w / m in / in 
    Hoffmann-La Roche Ltd.     Switzerland
  • Rocefin®
    powder d / infusion 
    Hoffmann-La Roche Ltd.     Switzerland
  • Steritsef®
    powdersolution for injections 
  • Tertsef®
    powdersolution w / m in / in 
    Aktavis, AO     Iceland
  • TOROCEF®
    powdersolution w / m in / in 
  • Triacson
    powdersolution w / m in / in 
  • Chizon
    powdersolution w / m in / in 
    Shin Pung Pharmaceutical Co., Ltd.     The Republic of Korea
  • Cefaxon
    powdersolution w / m in / in 
    Lupine Co., Ltd.     India
  • Cefatrine
    powdersolution w / m in / in 
  • Cefogram®
    powdersolution w / m in / in 
  • Cepheon
    powdersolution w / m in / in 
  • Cepheon
    powdersolution w / m in / in 
  • Ceftriabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Ceftriabol®
    powdersolution w / m in / in 
    PREBAND PFC, LLC     Russia
  • Ceftriaxone
    powdersolution d / infusion 
    KRASFARMA, JSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    KRASFARMA, JSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Ceftriaxone
    powdersolution w / m in / in 
    RUZFARMA, LLC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    RAFARMA, CJSC     Russia
  • Ceftriaxone
    powdersolution
    Mapichem AG     Switzerland
  • Ceftriaxone
    powdersolution w / m in / in 
    BIOSINTEZ, PAO     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
    LEKKO, ZAO     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
    Vertex Exports     India
  • Ceftriaxone
    powdersolution w / m in / in 
    BIOCHEMIST, OJSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution w / m in / in 
  • Ceftriaxone
    powdersolution
    SYNTHESIS, OJSC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    Company DEKO, LLC     Russia
  • Ceftriaxone
    powdersolution w / m in / in 
    MAKIZ-PHARMA, LLC     Russia
  • Ceftriaxone
    powder w / m in / in 
    HIMFARM, JSC     Kazakhstan
  • Ceftriaxone
    powder w / m in / in 
  • Ceftriaxone Danson
    powdersolution w / m in / in 
  • Ceftriaxone DS
    powdersolution
  • Ceftriaxone Kabi
    powdersolution w / m in / in 
  • Ceftriaxone Kabi
    powdersolution w / m in / in 
  • Ceftriaxone Protek
    powdersolution w / m in / in 
  • Elf Ceftriaxone
    powdersolution w / m in / in 
    ELFA NPC, CJSC     Russia
  • Ceftriaxone-Vial
    powdersolution w / m in / in 
    VIAL, LLC     Russia
  • Ceftriaxone-Jodhas
    powdersolution w / m in / in 
  • Ceftriaxone-CmP
    powdersolution w / m in / in 
  • Ceftriaxone-LEXMM®
    powdersolution w / m in / in 
  • Dosage form: & nbsp
    Powder for the preparation of solution for intramuscular injection. Powder for solution for intravenous administration.

    Composition:
    1 bottle with the drug contains:
    active substance: ceftriaxone sodium in terms of ceftriaxone 500 mg, 1000 mg.

    1 ampoule with a solvent for the preparation of a solution for intramuscular administration contains: lidocaine hydrochloride 2.0 ml, 3.5 ml.

    1 ampoule with a solvent for the preparation of a solution for intravenous administration contains: water for injection 5 ml, 10 ml.

    Description:
    White or white with a yellowish tint powder. Weakly hygroscopic. Solvent: Clear, colorless liquid.

    Pharmacotherapeutic group:Antibiotic-cephalosporin.
    ATX: & nbsp

    J.01.D.D.04   Ceftriaxone

    Pharmacodynamics:

    Cephson is a semi-synthetic cephalosporin antibiotic of the third generation of a broad spectrum of action.

    The bactericidal activity of Cephson is due to the suppression of the synthesis of cell membranes.The drug is highly resistant to the action of beta-lactamases (penicillinase and cephalosporinase) Gram-positive and Gram-negative microorganisms. Cephason is active against the following microorganisms:

    Gram-negative aerobes. Enterobacter aerogenes, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae (including strains resistant to ampicillin), Haemophilus parainfluenzae, Klebssiella spp. (including Klebssiella pneumoniae), Neisseria gonorrhoeae (including strains forming and non-treating penicillinase), Neisseria meningitidis, Proteus mirabilis, Proteus vulgaris, Morganella morganii, Serratia marcescens, Citrobacter freundii, Citrobacter diversus, Providencia spp., Salmonella spp., Shigella spp., Acinetobacter calcoaceticus.

    A number of strains of the above microorganisms that exhibit resistance to other antibiotics, such as penicillins, cephalosporins, aminoglycosides, are sensitive to ceftriaxone. Individual strains Pseudomonas aerugenosa are also sensitive to the drug.

    Gram-positive aerobes: Staphylococcus aureus (including strains that form penicillinase), Staphylococcus epidermidis (staphylococci, resistant to methicillin, are resistant to all cephalosporins, including ceftriaxone), Streptococcus pyogenes (beta-hemolytic group streptococci A), Streptococcus agalactiae (Group B Streptococcus), Streptococcus pneumoniae.

    Anaerobes. Bacteroides spp., Clostridium spp. (with the exception of Clostridium difficile).

    Pharmacokinetics:
    With intramuscular injection ceftriaxone is well absorbed from the site of administration and reaches high concentrations in the serum. Bioavailability of the drug is -100%. The average concentration in the plasma is achieved 2-3 hours after the injection. With repeated intramuscular or intravenous administration in doses of 500-2000 mg with an interval of 12 to 24 hours, there is accumulation of ceftriaxone in a concentration that is 15% -36% higher than the concentration achieved with a single injection. When administered at a dose of 1500 to 3000 mg, the half-life is between 5.8 and 8.7 hours; volume of distribution - from 5.78 to 13.5 liters; the plasma clearance is 0.58-1.45 l / h, the renal clearance is 0.32-0.73 l / h. Ceftriaxone reversibly binds to blood plasma proteins. From 33% to 67% of the drug is excreted unchanged by the kidneys, the remainder is excreted in the bile into the intestine, where biotransformed into an inactive metabolite.
    Penetration into the cerebrospinal fluid: in newborns and in children with inflammation of the meninges ceftriaxone penetrates into the cerebrospinal fluid, while in the case of bacterial meningitis, an average of 17% of the concentration of the drug in the plasma diffuses into the cerebrospinal fluid, which is approximately 4 times greater than with aseptic meningitis.24 hours after intravenous administration of ceftriaxone in a dose of 50-100 mg / kg body weight, concentrations in the cerebrospinal fluid exceed 1.4 mg / l. In adults with meningitis, 2-24 hours after the administration of 50 mg / kg of body weight, the concentration of ceftriaxone in the cerebrospinal fluid is many times greater than the minimal inhibitory concentrations for the most common meningitis pathogens.
    Indications:
    Infectious-inflammatory diseases caused by sensitive pathogens: sepsis; meningitis; disseminated borreliosis Lyme (early and late stages of the disease); infections of the abdominal cavity (peritonitis, biliary tract infections and gastrointestinal tract); infection of bones, joints, soft tissues, skin, as well as wound infections; infection in patients with weakened immunity; infections of the pelvic organs; infections of the kidneys and urinary tract; infections of the respiratory tract, especially pneumonia, and infections of the ENT organs; infections of the genitals, including gonorrhea.
    Prevention of infections in the postoperative period.
    Contraindications:
    Hypersensitivity to cephalosporins (including other cephalosporins, penicillins, carbapenems).

    Carefully:
    Assign the drug with ulcerative colitis, with violations of the liver and kidneys, with enteritis and colitis associated with the use of antibacterial drugs; premature and newborn children with hyperbilirubinemia; pregnancy and lactation.

    Pregnancy and lactation:
    The use of Cephson in pregnancy is possible only in cases where the intended benefit to the mother exceeds the potential risk to the fetus (ceftriaxone penetrates the placental barrier).
    If Cephson is needed during lactation, the question of stopping breastfeeding should be addressed (ceftriaxone excreted in breast milk).
    Dosing and Administration:

    The drug is administered intramuscularly or intravenously (drip, jet). Standard dosing regimen

    Adults and children over 12 years of age: for 1000-2000 mg once a day (every 24 hours). In severe cases or infections, the causative agents of which have only moderate sensitivity to ceftriaxone, the daily dose can be increased to 4000 mg. Newborns (up to 2 weeks): 20-50 mg / kg body weight once a day. The daily dose should not exceed 50 mg / kg of body weight.When determining the dose, there is no need to distinguish between full and premature babies.

    Infants and young children (from 15 days to 12 years): 20-80 mg / kg body weight once a day.

    Children with a body weight above 50 kg are prescribed doses for adults.

    Intravenous doses of 50 mg / kg or higher should be administered drip for at least 30 minutes.

    Patients of senile age: usual doses for adults, without adjustments for age. Duration of treatment depends on the course of the disease. As always with antibiotic therapy, Cephson administration should continue the patient for at least 48-72 hours after the temperature is normalized and the eradication of the pathogen is confirmed.

    Dosing in special cases

    When bacterial meningitis in infants and young children treatment is started with a dose of 100 mg / kg (but not more than 4000 mg) once a day. After identifying the pathogen and determining its sensitivity, the dose can be reduced accordingly. The best results with meningococcal meningitis were achieved with a treatment duration of 4 days, with meningitis caused by Haemophilus influenzae - 6 days, Streptococcus pneumoniae - 7 days.

    Borrelia Lyme: 50 mg / kg (the highest daily dose is 2000 mg) for adults and children over 12 years of age once a day for 14 days.

    Gonorrhea (caused by penicillinase-forming and penicillin-zoned strains): a single intramuscular injection of 250 mg of Cephson.

    Prevention of postoperative infections, depending on the degree of infectious risk, 1000-2000 mg of Cephson is administered once for 30-90 minutes before the start of the operation. In operations on the colon and rectum, simultaneous (but separate) administration of Cephson and one of 5-nitroimidazoles, for example, ornidazole, has proved to be well-established. In patients with impaired renal function there is no need to reduce the dose, if the function liver remains normal. The daily dose of Cephson should not exceed 2000 mg only in cases of preterminal renal failure (creatinine clearance less than 10 ml / min). In patients with hepatic dysfunction there is no need to reduce the dose, if the function kidneys remains normal. When combination of severe renal and hepatic insufficiency should regularly determine the concentration of ceftriaxone in the plasma and, if necessary, adjust its dose.

    Patients on dialysis additional introduction of the drug after dialysis is not required. It should, however, control the concentration of ceftriaxone in the serum for possible dose adjustment, since the rate of excretion of the drug in these patients may be reduced.

    Mode of application

    For intramuscular injection: The contents of the vial are dissolved as follows:

    Contents of the bottle The solvent (lidocaine solution hydrochloride 1 %)

    500 mg 2.0 ml

    1000 mg 3.5 ml

    After preparation, each ml of the solution contains about 250 mg in terms of ceftriaxone.

    As with other intramuscular injections, Cephson is injected into a relatively large muscle (gluteal gland); Trial aspiration helps to avoid unintentional insertion into the blood vessel. It is recommended to inject no more than 1000 mg of the drug into one muscle. Do not inject lidocaine solution intravenously.

    For intravenous administration: The contents of the vial are dissolved as follows:

    Contents of the bottle Solvent (water for injection)

    500 mg 5.0 ml

    1000 mg 10.0 ml

    After preparation, each ml of the solution contains about 100 mg in terms of ceftriaxone. The solution is administered slowly for 2-4 minutes.

    For intravenous infusion Dissolve 2000 mg of Cephson in 40 ml of sterile water for injection or one of the calcium-free infusion solutions (0.9% sodium chloride solution, 2.5%, 5% or 10% dextrose solution, 5% levulose solution, 6% dextran solution in dextrose) . The solution is introduced for 30 minutes.

    Side effects:

    Allergic reactions: Rash, fever or chills, skin rashes, itching, rare-bronchospasm, eosinophilia, exudative erythema multiforme (including Stevens-Johnson syndrome), serum sickness, anaphylactic shock.

    From the gastrointestinal tract: nausea, vomiting, diarrhea or constipation, flatulence, abdominal pain, taste disorder, stomatitis, glossitis, pseudomembranous enterocolitis, impaired liver function (increased activity of "liver" transaminases, less often - alkaline phosphatase or bilirubin, cholestatic jaundice), pseudo-cholelithiasis of the gallbladder ("sludge"-syndrome), a dysbacteriosis.

    From the hematopoiesis: anemia, leukopenia, leukocytosis, neutropenia, granulocytopenia, lymphopenia, thrombocytosis, thrombocytopenia, hemolytic anemia, hypocoagulation, a decrease in the concentration of flame coagulation factors (II, VII, IX, X), prolongation of prothrombin time.

    From the urinary system: renal dysfunction (azotemia, increased urea in the blood, hypercreatininaemia, glycosuria, cylindruria, hematuria), oliguria, anuria.

    Laboratory indicators: azotemia, increased urea concentration, hypercreatininaemia.

    Local reactions: phlebitis, soreness along the vein, soreness and infiltration at the site of intramuscular injection.

    Other: headache, dizziness, nosebleeds, candidiasis, superinfection.

    Overdose:
    In case of an overdose, hemodialysis and peritoneal dialysis will not reduce the concentration of the drug. There is no specific antidote. Treatment of an overdose is symptomatic.

    Interaction:
    Ceftriaxone, suppressing the intestinal flora, interferes with the synthesis of vitamin K. With simultaneous administration with drugs that reduce platelet aggregation (non-steroidal anti-inflammatory drugs, salicylates, sulfinpyrazone), the risk of bleeding increases. With a simultaneous appointment with anticoagulants, the effect of the latter is noted.
    With simultaneous administration with "loop" diuretics, the risk of developing nephrotoxic action increases.
    Ceftriaxone and aminoglycosides have a synergistic effect on many Gram-negative bacteria. Incompatible with ethanol.
    Pharmaceutical interaction
    Ceftriaxone solutions should not be mixed or administered simultaneously with other antimicrobial agents. Ceftriaxone Do not mix with solutions containing calcium.

    Special instructions:
    With simultaneous severe renal and hepatic insufficiency, in patients who are on hemodialysis, the concentration of the drug in the plasma should be regularly determined.
    With long-term treatment, it is necessary to regularly monitor the picture of peripheral blood, indicators of the functional state of the liver and kidneys.
    In rare cases with ultrasound of the gallbladder, blackouts are observed, which disappear after the cessation of treatment (even if this phenomenon is accompanied by pain in the right hypochondrium, it is recommended to continue antibiotic prescribing and symptomatic treatment). During treatment, the use of ethanol is contraindicated - disulfiramoid-like effects are possible (red face, stomach and stomach spasms, nausea,vomiting, headache, lowering blood pressure, tachycardia, dyspnea).
    Despite the detailed collection of anamnesis, which is the rule for other cephalosporin antibiotics, one can not exclude the possibility development of anaphylactic shock, which requires immediate therapy-first intravenously injected epinephrine, then glucocorticosteroids. In vitro studies have shown that, like other cephalosporin antibiotics, ceftriaxone is able to displace bilirubin associated with serum albumin. Therefore, in newborns with hyperbilirubinemia and, especially, in preterm infants, the use of ceftriaxone requires even greater caution. Elderly and debilitated patients may require the appointment of vitamin K. The prepared solution should be stored at room temperature for no more than 6 hours or in a refrigerator at a temperature of 2-8 ° C not more than 24 hours. Shake before use.


    Form release / dosage:
    Powder for the preparation of solution for intramuscular injection of 500 mg or 1000 mg.
    Packaging:
    Powder for the preparation of solution for intramuscular administration: 500 mg or 1000 mg per bottle of colorless glass, corked with bromobutyl rubber stopper, crimped aluminum ring or aluminum cap "flip off".Solvent (lidocaine hydrochloride solution 1%): 2 ml or 3.5 ml into a vial of colorless glass.
    For 1 bottle with the drug and 1 ampoule with a solvent, along with instructions for use in a cardboard pack.
    100 bottles of the drug are placed in a cardboard box (for hospitals) with instructions for use (50 pieces).
    Powder for the preparation of a solution for intravenous administration: 500 mg or 1000 mg per bottle of colorless glass, corked with bromobutyl rubber stopper, crimped
    aluminum ring or aluminum cap "flip off".
    Solvent (water for injection): 5 ml or 10 ml into a vial of colorless glass.
    For 1 bottle with the drug and 1 ampoule with a solvent, along with instructions for use in a cardboard pack.
    For 1 bottle with the drug and 1 ampoule with a solvent in a tray of polyvinyl chloride; 1 pallet together with instructions for use in a cardboard box. 100 bottles of the drug are placed in a cardboard box (for hospitals) with instructions for use (50 pieces).

    Storage conditions:
    At a temperature of no higher than 25 ° C, in a dry place protected from light, Keep out of the reach of children.

    Shelf life:3 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:П N014008 / 01
    Date of registration:10.06.2008
    The owner of the registration certificate:Mustafa Nevzat Ilach Sanai A.Sh.Mustafa Nevzat Ilach Sanai A.Sh. Turkey
    Manufacturer: & nbsp
    Representation: & nbspASFARMA-ROS LLCASFARMA-ROS LLCRussia
    Information update date: & nbsp24.11.2015
    Illustrated instructions
      Instructions
      Up